TECH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Techne Corp (TECH) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak technical indicators, bearish sentiment in options data, and limited positive catalysts. While analysts have raised price targets and the company has recurring revenue, the recent financial performance and lack of strong growth trends suggest waiting for a clearer entry point.
The technical indicators are bearish. The MACD is negative and contracting, RSI is neutral at 42.855, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 51.813, with key support at 49.154 and resistance at 54.472.
Analysts have raised price targets, with an average target of $74, indicating potential upside. The company has approximately 80% recurring revenue, which provides stability.
Hedge funds are aggressively selling, with a 5004.01% increase in selling activity last quarter. The stock has underperformed the market by 34 percentage points over the past year. Revenue growth is flat YoY, and gross margins have declined slightly. Additionally, Hollow Brook Wealth Management LLC sold its entire position in the company.
In Q2 2026, revenue dropped by -0.39% YoY to $295.88M, while net income increased by 8.93% YoY to $38.00M. EPS grew by 9.09% YoY to 0.24, but gross margin declined to 65.29%, down -1.43% YoY. The financials show mixed performance, with limited growth in revenue but slight improvements in profitability.
Analysts have mixed views: UBS, TD Cowen, and Citi maintain Buy ratings with price targets of $79-$80, reflecting optimism about long-term growth. However, Evercore ISI downgraded the stock to In Line, citing modest growth prospects. The average price target is $74, suggesting potential recovery but not immediate upside.
